For the year ending 2025-12-31, GLUE made $123,672K in revenue. -$39,097K in net income. Net profit margin of -31.61%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Collaboration revenue | 123,672 | |||
| Research and development | 141,500 | |||
| General and administrative | 36,380 | |||
| Total operating expenses | 177,880 | |||
| Loss from operations | -54,208 | |||
| Interest income | 12,942 | |||
| Foreign currency exchange gain, net | 1,484 | |||
| Gain on disposal of fixed assets | 59 | |||
| Total other income | 14,485 | |||
| Net loss before income taxes | -39,723 | |||
| Income tax benefit (provision) | -1,097 | |||
| Net loss | -38,626 | |||
| Provision for pension benefit obligation | -518 | |||
| Unrealized gain on available-for-sale securities | -47 | |||
| Comprehensive loss | -39,097 | |||
| Basic Average Shares | 83,071,185 | |||
| Diluted Average Shares | 83,071,185 | |||
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)